Last reviewed · How we verify
OBE2109
OBE2109 is a selective progesterone receptor modulator that modulates progesterone signaling to treat reproductive and gynecological disorders.
OBE2109 is a selective progesterone receptor modulator that modulates progesterone signaling to treat reproductive and gynecological disorders. Used for Uterine fibroids (heavy menstrual bleeding), Endometriosis-associated pain.
At a glance
| Generic name | OBE2109 |
|---|---|
| Sponsor | ObsEva SA |
| Drug class | Selective progesterone receptor modulator (SPRM) |
| Target | Progesterone receptor (PR) |
| Modality | Small molecule |
| Therapeutic area | Gynecology / Reproductive Health |
| Phase | Phase 3 |
Mechanism of action
OBE2109 acts as a selective progesterone receptor agonist/modulator, targeting the progesterone receptor to regulate endometrial and ovarian function. This mechanism is designed to address conditions related to abnormal uterine bleeding and reproductive dysfunction by modulating the effects of progesterone in target tissues.
Approved indications
- Uterine fibroids (heavy menstrual bleeding)
- Endometriosis-associated pain
Common side effects
- Hot flashes
- Headache
- Amenorrhea
- Vaginal bleeding abnormalities
Key clinical trials
- A Study to Assess the Efficacy and Safety of OBE2109 in Subjects With Endometriosis (PHASE2)
- Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PHASE3)
- Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids (PHASE3)
- Safety and Pharmacokinetics of Linzagolix in Female Subjects With Normal and Impaired Renal Function (PHASE1)
- Safety and Pharmacokinetics Study of Linzagolix in Female Subjects With Normal and Impaired Hepatic Function (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OBE2109 CI brief — competitive landscape report
- OBE2109 updates RSS · CI watch RSS
- ObsEva SA portfolio CI